Sims Andrew John Hugh MacIntyre 4

What Happened

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of Plus Therapeutics (PSTV), recorded the conversion/exercise of derivative securities (RSUs) on April 1, 2026. The filing shows acquisition of 38,323 and 29,129 shares (total 67,452) at $0.00 and corresponding dispositions of the same amounts at $0.00. The reported dollar value is $0, and the net reported change in holdings on this Form 4 is zero.

Key Details

• Transaction date: 2026-04-01
• Transaction type/code: M — Exercise or conversion of a derivative security (RSU conversion)
• Shares acquired: 38,323 and 29,129 (total 67,452) at $0.00
• Shares disposed: 38,323 and 29,129 (total 67,452) at $0.00 (reported as derivative disposition)
• Shares owned after transaction: Not specified in the provided data
• Footnotes: F1 — Each RSU converts to one common share. F2 — one RSU grant vests in 12 equal quarterly installments beginning Oct 1, 2025. F3 — another RSU grant vests in 12 equal quarterly installments beginning Apr 1, 2026.
• Timeliness: Filing date and report period are 2026-04-01 (no late filing indicated)

Context

• This filing reflects RSU conversion/vesting activity rather than an open-market purchase or a typical sale. The simultaneous acquisition and immediate disposition at $0.00 commonly indicates conversion/settlement mechanics (e.g., issuance and immediate surrender/settlement) but the Form 4 does not specify whether shares were retained, sold in the market, or surrendered for tax withholding. Such RSU vesting is typically routine compensation-related activity and does not by itself indicate management’s view on the company’s stock.